ORNA Lipid AX-6 |for invivo CAR |DC Chemicals

Cas No.:	3091405-00-1
Chemical Name:	ORNA Lipid AX-6
Synonyms:	ORNA Lipid AX 6，AX6
SMILES:	CCCCCCCCOC(CCC(=O)OCC12CC3CC(COC(=O)CCCN(CC)CC)(C1)CC(COC(=O)CCC(OCCCCCCCC)OCCCCCCCC)(C3)C2)OCCCCCCCC
Formula:	C₆₁H₁₁₃O₁₀N
M.Wt:	1020.57
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC67568	ORNA Lipid AX-6	AX6 is an ionizable lipid in the F32 LNP formulation, engineered by ReNAgade/Orna Therapeutics for targeted mRNA delivery to T cells. AX-6's unique bridged bicyclic/polycyclic core with a tertiary amine group enables pH-dependent protonation and endosomal escape, while C14-C18 hydrophobic tails (optionally branched/fluorinated) enhance bilayer stability and mRNA encapsulation. Demonstrating exceptional T-cell tropism, AX6 achieves high transfection efficiency in CD4+/CD8+ T cells (validated in NHP/humanized models) with minimal toxicity. Compared to clinical benchmarks (SM-102, ALC-0315), its rigid core offers superior serum stability and immune-cell specificity, positioning it as an ideal candidate for CAR-T/NK therapies and next-gen vaccines. The F32 LNP system's proven efficacy (e.g., in vivo B-cell depletion) underscores AX 6's transformative potential for cell engineering and immunotherapies.
DC67556	Sail Lipid 2308	Sail Lipid 2308 is a novel ionizable lipid targeting to spleen developed by Sai Biomedicine.As described on US20250205167A1, Lipid 2308 was designed with a piperidine core (6-membered ring) and asymmetric C17/C11 chains, this lipid achieves unprecedented spleen-specificity. It demonstrates dominant spleen accumulation (Spleen RLU: 7.8E+06, 91.8% of total signal) with a record spleen-to-liver ratio of 112.7 (9× higher than 2231). Despite lower protein expression (hEPO: 11,000 ng/mL), near-zero liver uptake (Liver RLU: 66,000) makes Lipid 2308 unparalleled for vaccine/immunotherapy applications targeting splenic immune cells.
DC67555	Sail Lipid 2231	Sail Lipid 2231 is a novel ionizable lipid targeting to spleen developed by Sai Biomedicine.As described on US20250205167A1 Lipid 2231 features a pyrrolidine core (5-membered ring) with biodegradable ester linkages and asymmetric C17/C11 hydrophobic chains. In vivo data shows moderate spleen targeting (Spleen RLU: 3.8E+06) with a spleen-to-liver ratio of 12.767.